# US 2001/0025048 A1 · Methods of use of antimicrobial compounds against pathogenic mycoplasma bacteria

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0025048 A1
- Document ID: US20010025048A1
- Status: Published application
- Kind: A1
- Application number: 09/853,854
- Filed: 2001-05-11
- Published: 2001-09-27
- Earliest claimed: 1999-06-29
- Assignees: SmithKline Beecham Corporation
- Inventors: Donna M. Crabb; Lynn B. Duffy; Karen B. Searcy
- Web page: https://patentgrep.com/patent/US20010025048A1

## CPC

- A61K 31/47: Quinolines; Isoquinolines
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against certain pathogenic bacteria.

## Claims

### Claim 1

A method for modulating metabolism of pathogenic Mycoplasma bacteria comprising the step of contacting pathogenic Mycoplasma bacteria with an antibacterially effective amount of a composition comprising a gemifloxacin compound, or antibacterially effective derivatives thereof.

### Claim 2 (depends on 1)

The method of claim 1 wherein said pathogenic Mycoplasma bacteria is selected from the group consisting of:
Mycoplasma pneumoniae, M. hominis, M. fermentans, M. genitalium, M. penetrans and Ureaplasma urealyticum.

### Claim 3

A method of treating or preventing a bacterial infection by pathogenic Mycoplasma bacteria comprising the step of administering an antibacterially effective amount of a composition comprising a gemifloxacin compound to a mammal suspected of having or being at risk of having an infection with pathogenic Mycoplasma bacteria.

### Claim 4 (depends on 3)

The method of claim 3 wherein said pathogenic Mycoplasma bacteria is selected from the group consisting of:
Mycoplasma pneumoniae, M. hominis, M. fermentans, M. genitalium, M. penetrans and Ureaplasma urealyticum.

### Claim 5 (depends on 1)

The method of claim 1 wherein said modulating metabolism is inhibiting growth of said bacteria.

### Claim 6 (depends on 1)

The method of claim 1 wherein said modulating metabolism is killing said bacteria.

### Claim 7 (depends on 1)

The method of claim 1 wherein said contacting said bacteria comprises the further step of introducing said composition into a mammal.

### Claim 8 (depends on 3)

The method of claim 3 wherein said mammal is a human.

### Claim 9 (depends on 7)

The method of claim 7 wherein said mammal is a human.

### Claim 10 (depends on 1)

The method of claim 1 wherein said bacteria is selected from the group consisting of: Mycoplasma pneumoniae, M. hominis, M. fermentans, M. genitalium, M. penetrans and Ureaplasma urealyticum.

### Claim 11 (depends on 1)

The method of claim 1 wherein said bacteria is selected from the group consisting of: Mycoplasma pneumoniae, M. hominis, M. fermentans, M. genitalium, M. penetrans and Ureaplasma urealyticum.
